As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...
The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application ...
The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...
Secured three additional regulatory approvals for world's first chikungunya vaccine, IXCHIQ ® (Canada, Europe, UK); filed adolescent label extension submissions; awarded new $41.3 million grant from ...
Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...
Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback